. 2017 Jul 31;13(7):e1006510. doi: 10.1371/journal.ppat.1006510

Table 2. Clinical characteristics of 6 participants from the acute HIV-1 infection cohort RV217.

Participant	NAT -conversion window ^a (days)	Peak viremia		Nadir viremia ^c	HIV Serology		Viral subtype ^e
Participant	NAT -conversion window ^a (days)	Day ^b	(log₁₀ copies/ml)	(log₁₀ copies/ml)	EIA-conversion (day) ^b	Western blot (day ^b; result ^d)	Viral subtype ^e
20225	4	d9	7.99	5.12	d14	d14 (P)	A1/C URF
40100	7	d10	8.46	5.71	d10	d10 (N); d17 (I); d24 (P)	CRF01_AE
40061	3	d14	5.79	3.55	d18	d18 (I); d21(I); d28 (P)	CRF01_AE
40436	2	d18	6.09	4.78	d14	d14 (I); d21(I); d28 (I); d35 (P)	CRF01_AE
10463	14	d13	6.62	4.59	d13	d13 (N); d20 (P)	A1/D URF
40265	2	d12	6.49	4.62	d19	d19 (N); d21(I); d28 (P)	CRF01_AE

^a NAT: Nucleic acid testing; Conversion window: time from last negative to first positive NAT.

^b days since first positive viremia.

^c Nadir viremia: lowest plasma viral load after the peak through d42.

^d N: negative; I: indeterminate; P: Positive.

^e URF: Unique recombinant form.